Breaking News: Trump Announces Plan to Lower IVF Drug Costs
On October 16, 2025, President Trump announced new initiatives aimed at expanding access to in vitro fertilization (IVF) and reducing fertility treatment costs. Key components of the announcement include:
- IVF Medication Discounts: EMD Serono will offer price reductions on key IVF medications—including Gonal-f, Ovidrel, and Cetrotide—through TrumpRx, a forthcoming government-sponsored platform.
- Workplace Fertility Benefits: Federal officials are releasing recommendations for employers to consider adding standalone infertility coverage, similar to vision or dental benefits. This effort will not include a federal mandate or subsidy.
- Accelerated FDA Review: The FDA has placed EMD Serono’s Pergoveris under priority review status, allowing for a faster approval process to bring the drug to market sooner.
These efforts are part of a larger goal to make fertility care more accessible and affordable nationwide in the years to come. As we await detail from the administration around the start date of these potential new programs, it’s important to note that time is a valuable resource in fertility care. If you’re experiencing infertility or struggling to build your family now, it’s important not to delay seeking help. A fertility specialist can diagnose the cause and guide you toward solutions, and many patients are able to conceive without IVF. For those who need advanced treatments, Reproductive Biology Associates (RBA) offers financing options to make care more accessible.
Future Impact at Reproductive Biology Associates
Here’s how this could affect patients at RBA in 2026 and beyond:
- If you’re already in treatment: Your current medication plan will remain the same for now. Once the new discount program begins, RBA will review your future treatment cycles to determine if you qualify for savings.
- If you’re planning IVF: Medication costs could decrease in 2026. The TrumpRx program does not yet have a confirmed start date, so pricing adjustments are not currently in effect.
- If your employer provides insurance: Some companies may start expanding coverage for IVF in the future. RBA can help you review your insurance benefits to see if new coverage options become available.
- For all patients: More affordable medication and improved coverage may help make fertility treatment accessible for a wider range of families. RBA will continue to keep patients informed as new details are announced.
What to Know
- The new pricing program is not active yet. It’s expected to start in 2026. There has been no confirmed date for pricing program launch.
- The discounts only apply to specific EMD Serono medications, which are not used in all treatment types or fertility care cycles.
- RBA will continue to follow these updates and support patients with clear information following new developments.
-
For the full details, visit the Prelude Network site here.
For more details, see: Reuters — White House set to announce proposal seeking to make IVF more accessible
Time is a valuable resource in fertility care - if you're experiencing infertility or struggling to build your family now, it's important to not delay seeking help. RBA is committed to helping every patient access high-quality, affordable fertility care – now and in the years to come.